OssDsign AB (OSSD) AI Stock Analysis

• Market Cap: kr1.02B
• Dividend Yield: N/A
• Average Volume (3M): 297.02K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.17
• Revenue Growth: 38.43%
• EPS Growth: 57.76%
• Country: SE
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.05
• Shares Outstanding: 110,597,374
• 10 Day Avg. Volume: 325,245
• 30 Day Avg. Volume: 297,022
• PEG Ratio: 0.29
• Price to Book (P/B): 4.57
• Price to Sales (P/S): 7.31
• P/FCF Ratio: -15.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr9.00 ▼(-20.35% Downside)

The score is primarily constrained by ongoing losses and negative free cash flow, despite strong gross margins and a very low-debt, well-capitalized balance sheet. Technicals also weigh on the score, with the share price below major moving averages and negative MACD, while valuation is difficult to justify on earnings due to the negative P/E.

Positive Factors

Gross Margins

Sustained ~96% gross margins signal a highly differentiated product with strong pricing power and low variable costs. This structural advantage supports scalable revenue growth and long-term margin expansion as fixed costs are absorbed and commercial traction increases.

Balance Sheet Strength

Extremely low leverage and sizable equity provide durable financial flexibility to fund R&D, clinical work, or selective M&A without immediate refinancing risk. This reduces insolvency risk and supports multi-quarter investment plans crucial for med-device commercialization.

Revenue Scaling

Consistent top-line growth demonstrates market adoption and validates the product offering. Continued revenue expansion increases operating leverage potential, improving the path to break-even and enabling reinvestment in commercial and product development over the medium term.

Negative Factors

Ongoing Unprofitability

Persistent negative net margins and losses show the business has not yet converted operational strengths into profits. Over time, sustained unprofitability erodes retained earnings, limits internal funding for growth, and increases reliance on external capital sources.

Negative Cash Flow / Cash Burn

Material negative operating and free cash flows indicate ongoing cash burn that must be financed externally. Continued outflows constrain strategic options, risk dilutive capital raises, and could force spending cuts that impair long-term R&D, regulatory, or commercial plans.

Low Capital Efficiency

Negative ROE reflects inefficient use of shareholder capital: despite strong gross margins, management has not yet produced positive returns. Prolonged weak capital efficiency risks investor confidence and limits non-dilutive funding options for strategic initiatives.

OssDsign AB Business Overview & Revenue Model

Company Description

OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.

How the Company Makes Money

OssDsign AB generates revenue through the sale of its proprietary biomaterial implants and related products in the medical field. The company primarily earns income from hospitals and surgical centers that purchase its custom implants for use in surgical procedures. Key revenue streams include direct sales of their products, which are often billed to healthcare providers or insurance companies, as well as potential royalties from partnerships with larger medical device companies that may license OssDsign's technology. Additionally, the company may benefit from collaborations with research institutions and participation in clinical trials, which can enhance its market presence and drive further sales.

OssDsign AB Financial Statement Overview

Summary

Strong balance sheet with minimal leverage (debt-to-equity ~0.005) and very high gross margins (~96%) are key positives. However, the company remains unprofitable (TTM net margin ~-23.7%, ROE ~-15.1%) and continues to burn cash (TTM operating cash flow ~-54.2M; free cash flow ~-57.9M), keeping the score below average despite improving trends.

Income Statement

Revenue has scaled materially over the last several years, with TTM (Trailing-Twelve-Months) revenue up ~4.9% versus the prior period and very strong gross margins (TTM ~96%). However, the company remains structurally unprofitable: TTM operating and net margins are still meaningfully negative (net margin ~-23.7%), even though losses have improved substantially from 2021–2023 levels. Overall, the top-line and gross profitability profile is a clear strength, but ongoing operating losses keep the income statement score below average.

Balance Sheet

The balance sheet is a key positive. Leverage is minimal (TTM debt-to-equity ~0.005), and equity is sizable relative to assets, indicating strong capitalization and financial flexibility. The main weakness is negative returns on equity driven by persistent net losses (TTM ROE ~-15.1%), which signals that profitability has not yet caught up to the capital base despite improving trends.

Cash Flow

Cash generation remains weak, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both negative (approximately -54.2M and -57.9M, respectively), implying continued cash burn to fund operations. While cash burn appears to be improving versus prior years (free cash flow growth is positive in the latest periods), the business has not yet demonstrated an ability to consistently fund itself internally, which weighs heavily on the cash flow score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	176.48M	133.94M	112.16M	56.98M	31.73M	24.87M
Gross Profit	170.12M	127.75M	83.64M	45.13M	20.84M	16.00M
EBITDA	-37.43M	-45.31M	-122.02M	-89.41M	-79.97M	-80.64M
Net Income	-41.76M	-49.66M	-130.49M	-99.39M	-93.92M	-84.59M
Balance Sheet
Total Assets	430.71M	307.42M	356.39M	339.50M	343.99M	246.65M
Cash, Cash Equivalents and Short-Term Investments	210.86M	100.86M	165.94M	124.65M	151.37M	49.40M
Total Debt	1.64M	1.97M	3.15M	13.60M	14.13M	17.24M
Total Liabilities	83.43M	93.36M	105.26M	91.39M	81.26M	134.58M
Stockholders Equity	347.27M	214.06M	251.13M	248.11M	262.72M	112.07M
Cash Flow
Free Cash Flow	-57.88M	-63.04M	-94.03M	-89.36M	-89.84M	-81.59M
Operating Cash Flow	-54.18M	-62.38M	-93.91M	-89.23M	-89.78M	-79.10M
Investing Cash Flow	-5.16M	-657.00K	-124.00K	-129.00K	-51.85M	-17.67M
Financing Cash Flow	161.74M	-2.46M	135.40M	61.84M	243.43M	33.18M

OssDsign AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 11.3 is above the 20-day moving average (MA) of 10.24, above the 50-day MA of 10.86, and below the 200-day MA of 13.20, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 28.63 is Positive, neither overbought nor oversold. The STOCH value of 16.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.07B	45.72	6.93%	―	-5.80%	-65.99%
PAX	52 Neutral	kr1.08B	171.03	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	kr997.34M	-24.54	-4.42%	―	13.48%	28.98%
OSSD	46 Neutral	kr1.02B	-22.47	―	―	38.43%	57.76%
BACTI.B	46 Neutral	kr606.26M	-28.50	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr786.08M	-5.77	-36.55%	―	62.24%	21.16%